Design And Development Of A Novel Formulation Of Pacritinib For Treatment Of Adults Intermediate And High Risk Myelofibrosis With Low Platelet Count

Authors

  • Subhakanta Kanungo, Dr. Santosh kumar Panda

DOI:

https://doi.org/10.47750/pnr.2023.14.S01.84

Abstract

Cancer is the leading cause of mortality and morbidity after the heart diseases across the globe which affected 9.3 million lives in year 2018. Sustained release and extended-release dosage forms have the advantage of better patient compliance and low dosing frequency. Although they have a potential threat of dose dumping, several attempts have been made by pharmaceutical scientists to develop sustained and extended-release drug delivery systems. Pacritinib citrate is a drug of choice for myelofibrosis. It is a macrocyclic protein kinase inhibitor. Myelofibrosis is a rare blood cancer where scar tissue forms in your bone marrow. It’s a type of chronic leukemia that involves too many abnormal blood cells being made. Eventually, these cells can replace normal cells. Treatment goals mainly involve managing symptoms and conditions that arise, including anaemia and an enlarged spleen. The present work involves formulation of Sustained release tablets of Pacritinib citrate by using various hydrophilic polymers like HPMC 15 CPS, HPMC K4M, HPMC K15 MCR, HPMC K100 MCR and Ethyl cellulose 20cps. Dry granulation and wet granulation techniques were evaluated for the preparation of tablets. The formulated tablets were subjected to various evaluation tests like weight variation, hardness, assay, disintegration and dissolution tests. Finally, it was concluded that the F3 batch shows the best results, amongst all formulated batches. 

Downloads

Published

— Updated on 2023-01-15

Issue

Section

Articles

How to Cite

Design And Development Of A Novel Formulation Of Pacritinib For Treatment Of Adults Intermediate And High Risk Myelofibrosis With Low Platelet Count. (2023). Journal of Pharmaceutical Negative Results, 649-652. https://doi.org/10.47750/pnr.2023.14.S01.84